Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Recruiting

Phase 3

Radiation & HER2-targeted TherapyTesting Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Sponsor:

NRG Oncology

Code:

NCT05705401

Conditions

HER2-positive Breast Cancer

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Standard of Care Adjuvant Breast Radiation

Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-19. This information was provided to ClinicalTrials.gov by NRG Oncology on 2025-05-04.